Last checked at 25 Apr 2014 07:00
25 April 2014
Allergy Therapeutics plc
("Allergy Therapeutics" or "the Company")
Grant of Options
Allergy Therapeutics plc (AIM: AGY) announces that, pursuant to the Allergy Therapeutics plc Long Term Share Incentive Plan ('LTIP') on 24 April 2014 provisional shares of 0.1 pence each in the share capital of the Company were awarded to the following Board Directors, Mr Manuel Llobet (Chief Executive Officer) and Mr Ian Postlethwaite (Finance Director) at nil cost, as follows:
Director | Number of provisional shares awarded | Date of distribution | Total provisional shares held under LTIPs |
Manuel Llobet | 845,000 | 24 April 2014 | 3,190,000 |
Ian Postlethwaite | 422,500 | 24 April 2014 | 1,595,000 |
The issuance and distribution of ordinary shares of 0.1 pence each under the LTIP is conditional on the Company's performance over the course of three years. The new Long Term Incentive Plan was adopted by the Board on 20 March 2013.
-Ends-
For further information
Allergy Therapeutics | +44 (0) 1903 845 820 |
Manuel Llobet, Chief Executive Officer | |
Ian Postlethwaite, Finance Director | |
www.allergytherapeutics.com | |
Peel Hunt LLP | +44 (0) 20 7418 8900 |
James Steel / Clare Terlouw | |
FTI Consulting | +44 (0) 20 3727 1000 |
Simon Conway/ Mo Noonan / Victoria Foster-Mitchell |
Notes to editors
About Allergy Therapeutics
Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving sales in the prior financial year of almost £40 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets.